Mortality Due to COVID-19 in the COVID-AGEBRU Study
- Conditions
- Old Age; DebilityCovid19Morbidity, Multiple
- Registration Number
- NCT04756479
- Lead Sponsor
- Brugmann University Hospital
- Brief Summary
The COVID-Age Brugmann study aims to identify the clinical predictors of mortality risk in older patients admitted to an acute care unit due to COVID-19
- Detailed Description
The COVID-19 disease has been shown to be associated to higher mortality risk and health adverse consequences. Despite of the fact that the SAR-COV2 virus has been shown that affects every populations, the negative impact is higher in older people, pointing this population as the most severely affected.
The COVID-Age Brugmann study aims to identify if comorbidity, geriatric syndromes, and health issues at admission are associated to mortality risk in older patients admitted to an acute care unit due to COVID-19
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
- Patients aged 70 and older
- Patients admitted to an acute care geriatric unit due to COVID-19
- Patients with COVID-19 by PCR, serology or CT scan suggestive of this disease
- No other demographic or clinical exclusion criteria will be applied
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All-cause mortality during hospital admission (admission up to discharge time) Through study completion, an average of one month. Vital status was obtained from medical records
- Secondary Outcome Measures
Name Time Method Prevalence of medical diseases and geriatric syndromes Through study completion, an average of one month. Clinical and demographical conditions, and geriatric syndromes
Trial Locations
- Locations (1)
CHU Brugmann
🇧🇪Brussels, Belgium